3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Melanoma
1
Kidney Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
10
Filgrastim
7
Ifosfamide
4
Carboplatin
4
aldesleukin
3
Temozolomide
3
Peripheral Blood Stem Cell Transplantation
3
Drug Therapy
3
Docetaxel
3
Cyclophosphamide
3
Counseling
3
fludarabine phosphate
2
fludarabine
2
etoposide phosphate
2
cemiplimab
2
belinostat
2
atezolizumab
2
Thiotepa
2
Surveys and Questionnaires
2
Radiotherapy
2
Nivolumab
2
Methods
2
Metformin
2
Early Intervention, Educational
2
Doxorubicin
2
Bupropion
2
Blood Specimen Collection
2
Amifostine
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
valspodar
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
Gynecologic
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled